Dynavax Technologies’ (DVAX) Outperform Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a research report released on Friday,RTT News reports. William Blair also issued estimates for Dynavax Technologies’ Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.28 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.61 EPS.

A number of other research analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a report on Friday. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price objective for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $13.33 on Friday. The stock’s 50-day simple moving average is $12.82 and its two-hundred day simple moving average is $12.04. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.05. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of 74.06 and a beta of 1.32.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. The firm had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Research analysts forecast that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Dynavax Technologies

A number of hedge funds have recently added to or reduced their stakes in DVAX. US Bancorp DE increased its stake in shares of Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 1,169 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Dynavax Technologies during the 4th quarter valued at about $35,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Dynavax Technologies during the 3rd quarter valued at about $45,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.